Kornimate/medical-research-clean huggingface dataset:
head down position for successful recanalization of anterior circulation large vessel occlusion (hopes4)

Conditions: Ischemic Stroke

Summary: this is a prospective, randomized, open label, blinded-end point, single-center study, aiming to investigate the effect of head down position in anterior circulation large vessel occlusion patients with successful recanalization after endovascular treatment.


Eligibility criteria:
inclusion criteria: * age ≥ 18 * anterior circulation large vessel occlusion who received endovascular treatment within 24 hours of stroke onset; * national institute of health stroke scale (nihss) ≥ 6 before endovascular treatment; * successful recanalization (mtici 2b-3) after endovascular treatment; * cerebral circulation time based on dsa of the stroke side was slower than that of the healthy side after successful recanalization; * aspects ≥ 6 on ct or dwi; * absence of parenchymal hematoma on ct images done in the angio suite immediately after the procedure; * modified rankin scale score before stroke onset ≤ 1; * signed informed consent by patient or their legally authorized representative. exclusion criteria: * hemorrhagic stroke: cerebral hemorrhage, subarachnoid hemorrhage; * severe hepatic or renal dysfunction, increase in alt or ast (more than 2 times of upper limit of normal value), increase in serum creatinine (more than 1.5 times of upper limit of normal value) or requiring dialysis; * after recanalization, severe and sustained (i.e., \> 5 minutes) uncontrolled hypertension (systolic blood pressure over 180mmhg or diastolic blood pressure over 105 mmhg) refractory to antihypertensive medication; * more than four retrieval attempts in the same vessel; * cardiac insufficiency (nyha class ≥ii); * pregnancy, plan to get pregnant or during lactation; * the estimated life expectancy is less than 6 months due to other serious diseases; * other conditions unsuitable for this clinical study assessed by researcher.
peginterferon alfa-2a, ribavirin and epoetin β in coinfected patients hcv/hiv not responding to previous treatment regimens

Conditions: Hepatitis C; HIV Infections

Summary: this trial will assess the sustained virologic response to treatment with peginterferon alfa-2a combined with high-dose ribavirin in human immunodeficiency virus (hiv)-infected patients with hepatitis c virus (hcv) genotype 1 or 4 coinfection and persistent transaminase elevations. these patients will have been nonresponders to previous regimens with peginterferon alfa and ribavirin therapy at a dosage of 800-1200 mg/d.

the purpose in treating chronic hcv infection in hiv-coinfected individuals is to clear hcv-rna antibodies and cure the infection. studies have shown that high doses of ribavirin are associated with higher response rates than those achieved with ribavirin at dosages of 800-1200 mg/d. the main aim of this trial is to assess the sustained virologic response to treatment with peginterferon alfa-2a plus high-dose ribavirin in hiv-infected patients coinfected with hcv genotypes 1 or 4 who have had persistent transaminase elevations and lack of response to previous treatment with peginterferon alfa and ribavirin at dosages of 800-1200 mg/d. the second aim will be to measure changes in serum hcv-rna titers and the percentage of patients achieving serum viral loads of \< 50 iu/ml during treatment. finally, we also intend to evaluate the safety of this treatment regimen.

Eligibility criteria:
inclusion criteria: * hiv-infected patients coinfected with hcv genotypes 1 or 4 * persistent transaminase elevation * nonresponders to previous treatment with peginterferon alfa plus ribavirin at a dosage of 800-1200 mg/d. exclusion criteria: * patients who abandoned treatment with peginterferon plus ribavirin before 12 weeks * patients with child-pugh b or c cirrhosis

Keywords: ribavirin non-responders hcv co-infected patients sustained virological response treatment experienced
reduction of preoperative anxiety in children: electronic tab vs midazolam

Conditions: Paediatric Outpatient Surgery

Summary: rationale: the most frequently used means to prevent pre-anaesthetic anxiety in children is a drug premedication. midazolam, a benzodiazepine, is mainly used. it requires time for action, so coordination between departments and operating room, exposed to the risks of side effects and failure and this variability action. alternative means were evaluated, such as the presence of parents during anaesthetic mask induction, distraction by clowns, hypnosis or video games. electronic tabs are small devices; light, easy to use with age-specific and interactive programs. our hypothesis is that these electronic tabs are more effective in reducing anxiety and distract children compare to preoperative medication. methods: this is a monocentric, randomized, open-label study comparing patients aged 4 to 10 years old programmed for a short term and low level of pain outpatient surgery. my pass score will be measured when arriving at the hospital, at the time of the separation with the parents, at the time of the anaesthetic mask induction and after the surgery. 118 patients will be randomized as follows : * arm 1 : hypnovel® (midazolam) * arm 2 : electronic tab the recruitment is performed by general practitioners in the lyon area.


Eligibility criteria:
inclusion criteria: * girls and boys aged 4 to 10 years, * american society of anesthesiologists score between 1 and 3, * programmed outpatient surgery for a short term and low level of pain * infection with influenza a virus confirmed with a quick diagnostic test, * informed consent from both parents exclusion criteria: * patients younger than 4 or older than 10 years old * preexisting psychiatric disorder with pedo-psychiatric follow-up * children with intellectual disability * psychotropic referred to anxiolytic and / or antipsychotic * history of surgery (n\>=3) * refusal to participate

Keywords: outpatient surgery anaesthesia midazolam electronic tab
effects of ankle weighted cuffs training in autism children

Conditions: Autism Spectrum Disorder

Summary: autism spectrum disorders (asd) are a diverse group of conditions. they are characterized by some degree of difficulty with social interaction, communication and behaviors. kinesthetic awareness can be defined as how we sense our body and the way it moves. this person might have difficulty understanding where their body is in relation to other objects, thus appearing clumsy, knocking things over, dropping items or misjudging personal space and thus standing too close to others.

the current study will be randomized control trial and data will be collected from (psrd) pakistan society rehablitation of the disabled. the study will include 44 patients equally divided into two groups and randomly allocated. inclusion criteria for the study will be a parent-confirmed asd diagnosis from a psychiatrist or licensed psychologist, both male and female children, age between 4 to 14 years. children with a history of lower limb surgery, a recent (\<1 year) ankle sprain and severe behavioral disturbances will be excluded from the study. experimental group will have ankle weighted cuffs while performing routine physical therapy exercises. control group will perform routine physical therapy exercises. outcomes will be analyzed by limb position sense test and 50 ft walk test. data collection will be done before and after the intervention. data will be analyzed through spss version 25.00.

Eligibility criteria:
inclusion criteria: * a pre-diagnosed autism spectrum disorder from a psychiatrist or licensed psychologist. * both male and female children. * age between 4 to 14 years. exclusion criteria: * children with a history of lower limb surgery. * children with a recent (\<1 year) ankle sprain. * children presented severe behavioral disturbances, such as aggressive behaviors, self- injurious behaviors, severe motor hyperactivity

Keywords: kinesthetic awareness toe walking ankle weighted training autism spectrum disorder
vaccine acceptance in pregnant minority women

Conditions: Pregnancy

Summary: the purpose of study will be to test two vaccine education strategies to learn how they impact flu and pertussis (tdap) vaccination rates and attitudes regarding vaccination during pregnancy after participating in the intervention. the education strategies will be based on the elaboration likelihood model (elm). this model is based on experimental psychology and has been previously used to increase breast cancer screening rates. these education strategies will be delivered through routine prenatal care visits to black/african-american women in atlanta.


Eligibility criteria:
inclusion criteria: * pregnant, expecting delivery between august 31, 2012 and june 30, 2013 * between the ages of 18-50 years old * black/african american exclusion criteria: * have received the influenza or tdap vaccine during the current pregnancy * already enrolled in the study

Keywords: pregnancy, vaccine acceptance, vaccination, influenza, pertussis, tdap, minority, african-american
intracranial rescue stenting for acute ischemic stroke, predictors of outcomes

Conditions: Ischemic Stroke; Thromboembolic Stroke

Summary: the use of rescue intracranial stenting is thought to be associated with better outcomes than with patients received medical treatment only after failed thrombectomy as reperfusion technique. this raised the questions about the factors that affect outcomes of rescue intracranial stenting angioplasty, so the best outcomes can be achieved.

mechanical thrombectomy is the first line therapy in acute ischemic stroke due to large vessel occlusion. recently, there is an increasing number of patients with failed re perfusion after mechanical thrombectomy, due to preexisting high degree of intracranial stenosis or failed mechanical thrombectomy. this is associated with poor clinical and functional outcome for the patients. the percentage of patients with failed mechanical thrombectomy is as high as 40-45% of all patients with ischemic stroke due to large vessel occlusion. this group is in need for rescue intracranial stenting to achieve re-canalization of the occluded vessel and restore perfusion. the results demonstrated superiority of medical management over stenting with less complications and this had almost put the intracranial stenting to rest for years. the main complication related to rescue stenting are ischemic complications especially thromboembolic events related to thrombus detachment, symptomatic intracerebral hemorrhage and re-stenosis of cerebral arteries after stenting. recently, the results of the chinese angioplasty and stenting for symptomatic intracranial severe stenosis trial and the wingspan stent system post market surveillance study (weave trial) showed that most of complications are related to peri-procedural techniques. this raise the interest again in the efficacy of intracranial stenting as treatment modality for selected patients. the use of rescue intracranial stenting is thought to be associated with better outcomes than with patients received medical treatment only after failed thrombectomy as reperfusion technique. this raised the questions about the factors that affect outcomes of rescue intracranial stenting angioplasty, so the best outcomes can be achieved.

Eligibility criteria:
inclusion criteria: 1. patients with acute ischemic stroke due to large vessel occlusion as confirmed by ct angiography or magnetic resonance (mr) angiography. 2. baseline nihss \>6. 3. presenting within the first 6 hours from onset of symptoms. 4. first ever stroke or pre-stroke modified rankin score (mrs) ≤1. exclusion criteria: 1. patients with intra cranial hemorrhage. 2. patients younger than 18 years. 3. patients with acute ischemic stroke due to small vessel disease or vasculitis. 4. patients with acute ischemic stroke due to occlusion of vessels of posterior circulation. 5. patients who refused to be included in the study. 6. patients with contraindications to intracranial stent placement (as total occlusion of artery).
elimination of vpb with ablation versus anti-arrhythmic drug treatment

Conditions: Ventricular Premature Beats

Summary: the ectopia trial is a randomized, multicenter, clinical trial to assess elimination of ventricular premature beats (vpb) with catheter ablation versus optimal anti-arrhythmic drugs (aad) treatment with flecainide/verapamil or sotalol.

the ectopia trial is a randomized, multicenter, clinical trial to assess elimination of vpb with catheter ablation versus optimal aad treatment with flecainide/verapamil or sotalol. due to the use of different aad (with and without beta-blocking abilities) the investigators will be able to explore the secondary objectives. finally, this study will assess safety of ablation of non-rvot vpbs and long-term treatment with two different aad.

Eligibility criteria:
inclusion criteria: * patients willing and capable to provide written informed consent * patients with frequent symptomatic vpb and/or nonsustained vts with burden ≥ 5% on 24 hour holter monitor and * absence of structural heart disease (excluded by echocardiogram) and * absence of underlying cardiac ischemia (ruled out by treadmill test, ct coronary arteries, nuclear scintigraphy or coronary angiography) and * patient is considered an acceptable candidate for catheter ablation treatment with a dominant morphology of vpb/vt origin judged by the treating physician. * for those already undergoing treatment, all antiarrhythmic drugs including digitalis must be discontinued during a 2-week washout period before entry to the study exclusion criteria: * age \>75 years * previous catheter ablation therapy for vpb/vt * patients with sustained ventricular tachycardia or cardiac channelopathies (e.g. catecholaminergic polymorphic ventricular tachycardia (cpvt), long- or short qt syndrome, brugada syndrome) * wolff-parkinson-white (wpw) syndrome * use of medication with risk of qtc prolongation (e.g. antidepressant, antiemetic), except for study medication sotalol. * left ventricular dysfunction (lv ejection fraction \<55%) * estimated glomerular filtration rate \< 50 ml/min/1.73 m2 * hepatic impairment defined by a total bilirubin ≥ 2 times the upper limit (uln) of normal, or alanine aminotransferase (alat) or aspartate aminotransferase (asat) ≥ 3 times uln at screening * untreated hypo- or hyperthyroidism or electrolyte imbalance * untreated obstructive sleep apnea * patients with history of myocardial infarction or bypass surgery * more than grade 1/3 valvular regurgitation and/or significant valve stenosis (moderate or severe) * contraindication for any of the antiarrhythmic drugs used in this study * enrolment in another clinical study * woman currently pregnant or breastfeeding or not using reliable contraceptive measures during fertile age * mental or physical inability to participate in the study * life expectancy ≤ 12 months
a multi-centered study of the long-term effect of salmeterol and albuterol in cystic fibrosis

Conditions: Cystic Fibrosis

Summary: long term use of bronchodilators in cf is beneficial to the improvement of pulmonary function and symptoms. this study is investigating the long-term benefit of administration of the drug salmeterol, a bronchodilator. salmeterol will be compared to albuterol or placebo. the medication will be inhaled twice a day for 6 months.

patients that have been diagnosed with cystic fibrosis and are above 5 years and below 45 years of age are eligible. subjects will be randomized into 1 of 3 groups. one group will get salmeterol by multi-dose inhaler (mdi) 2 puffs 2 times a day, one group will get albuterol by mdi 2 puffs 2 times a day and the other will get placebo by mdi 2 puffs 2 times a day. height and weight along with pulmonary function testing and vital signs will be monitored at the beginning of the study and at visits 2, 3, and 4. peak flow monitoring will be done each morning before study medication at home. a daily diary will be kept of this measurement. subjects will be seen in the research center at visits 1,2,3, and 4. telephone contact will be done at day 15, 60, 120, and 150. individual outcomes include a potential increase in pulmonary function testing and a decrease in frequency of pulmonary exacerbations, hospitalizations, and usage of antibiotics.

Eligibility criteria:
inclusion criteria: * ability to perform reproducible spirometry * fevi \> 50% and \< 90% (knudsen) * a cf pulmonary exacerbation within the last year or an fevi\<80% * at least one delta f508 allele on cf mutation analysis * ability to demonstrate use of inhaled medicine and fevi and pefr monitor * written informed consent * negative serum pregnancy test on enrollment
pilot study evaluating the safety and potential trends in efficacy of adhexil

Conditions: Bilateral Ovarian Disease

Summary: the objective is to evaluate the safety and initial efficacy of the omrix anti-adhesion (aa) kit, adhexil™ in preventing and/or reducing post-operative adhesions in patients undergoing surgery involving the ovaries.

adhexil™ contains the components that form the anti-adhesive barrier, bac and thrombin. thrombin is a sterile solution, containing highly purified human thrombin. bac is a sterile, solution whose principal component is a concentrate of human fibrinogen. adhexil™ is supplied in two vials and an application device.

Eligibility criteria:
inclusion criteria: * female patients aged 18-45 years at screening * patients undergoing elective laparoscopic surgery due to known or suspected bilateral ovarian disease exclusion criteria: * pregnant (including ectopic pregnancy) or breastfeeding patient * patients with a documented diagnosis of cancer * patients with a lymphatic, hematologic or coagulation disorder * patients with a known or suspected hypersensitivity to blood, blood products or any constituent of adhexil™ * patients who are immunocompromised, possess autoimmune disorders, or who are routinely taking anticoagulants. * patients who have participated in another clinical study within 30 days of enrolment. * investigator's opinion that the patient is medically unfit or would be at major risk if enrolled into the study.
ranibizumab for polypoidal choroidal vasculopathy (pcv)

Conditions: Polypoidal Choroidal Vasculopathy

Summary: this is a 12 month study of monthly injections of ranibizumab in subjects with polypoidal choroidal vasculopathy as diagnosed by fluoresceins/indocyanine green (fa/icg) angiography.

previous treatment in subjects is allowed as long as appropriate washout period has elapsed. patients will be followed by 4m etdrs vision testing as well as scheduled oct, icg, fa and fundus photography.

Eligibility criteria:
inclusion criteria: * ability to provide informed consent and comply with study assessment for the duration of one year * age \>= 25 years * polypoidal choroidal vasculopathy as noted on fluorescein and icg angiography: active leakage, active bleeding or recent decrease in vision * bcva using etdrs 20/32 to 20/400 exclusion criteria: * any history of previous vitrectomy * previous cataract or ocular surgery within 2 months of day 0 * active intraocular inflammation in the study eye * active infections conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye * participation with another investigational drug within the past 30 days * prior sodium pegaptanib, verteporfin photodynamic therapy, intravitreal steroids, or bevacizumab within 30 days of study entry * blood pressure \>180/110 (use of antihypertensives is allowed as long as hypertension can be controlled and is stable) * pregnancy

Keywords: choroidal neovascularization
dmek versus dsaek study

Conditions: Fuchs' Endothelial Dystrophy

Summary: the purpose of this study is to determine whether corneal transplantation by descemet membrane endothelial keratoplasty more favourable and cost-effective is compared to descemet stripping automated endothelial keratoplasty for fuchs endothelium corneal dystrophy.

fecd is a progressive, multifactorial and irreversible disease characterized by accelerated loss of corneal endothelial cells in the innermost layer of the cornea that leads to vision impairment and potential blindness if left untreated. fecd is responsible for more than 50% of the 1.300 annual corneal transplantations in the netherlands. corneal transplantation improves vision and quality of life in patients with corneal disease. currently, the standard of care for patients with fuchs endothelial corneal dystrophy (fecd) is descemet stripping automated endothelial keratoplasty (dsaek), in which only the posterior layers of the cornea are transplanted. however, visual recovery following dsaek is suboptimal. descemet membrane endothelial keratoplasty (dmek), the latest technique in corneal transplantation involves transplantation of only a monolayer of corneal endothelium and descemet's membrane providing the thinnest endothelial graft possible. dmek has been suggested to result in faster and better visual recovery compared to dsaek. while the economic burden, both medical and social, from this disease has not been assessed to date, costs associated with corneal transplantation reach $ 110 million dollars yearly for the 47.000 transplantations in the usa. the objective of this project is to assess the effects and costs of dmek vs. dsaek in order to determine whether the new technique is effective and cost-effective over the standard technique. the primary outcome measure is best-corrected visual acuity. secondary outcome measures are contrast acuity, astigmatism, quality of vision, endothelial cell loss, incidence of graft rejection, primary graft failure, cornea donor loss due to preparation, and generic and vision-related quality of life.

Eligibility criteria:
inclusion criteria: * cornea decompensation caused fuchs endothelial corneal dystrophy exclusion criteria: * ocular comorbidities other than cataract * previous corneal transplantation * human leukocyte antigen (hla) matched keratoplasty * inability to complete follow-up